SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-08-05
👔
First Tracks Biotherapeutics, Inc.
@TRAX_InsiderForm 4 Filing: Faga Daniel Acquires (Grant) shares of $TRAX
STOCK AWARD / GRANT
⚡ MATERIALITY: 2/10
corporate issuer
First Tracks Biotherapeutics, Inc.
Ticker: $TRAX
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-08-02
Shares: 193,576
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Faga Daniel, holds the title of President, CEO at First Tracks Biotherapeutics, Inc..
On 2026-08-02, the insider transacted 193,576 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Faga Daniel (President, CEO) was granted $0 of $TRAX
Post-Transaction Position: 387,156 shares
SEC Accession No: 0001673528-26-000014 (CIK: 1673528)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.